Simulations Plus Inc (SLP) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, positive news catalysts, and optimistic revenue forecast outweigh the neutral trading sentiment and lack of immediate trading signals. The stock's current pre-market price of $14.55 is near its pivot level, presenting a reasonable entry point.
The MACD is positive at 0.237, indicating bullish momentum, although it is contracting. RSI is neutral at 52.692, and moving averages are converging, suggesting no strong directional trend. The stock is trading near its pivot level of $14.17, with key resistance at $15.352 and support at $12.987.

Partnership with Lonza and the FDA to enhance regulatory confidence in drug products.
Strong Q2 FY2026 financial results with 8% revenue growth, 47.53% net income growth, and a 46.67% EPS increase.
Optimistic full-year revenue forecast of $79 million to $82 million.
Analyst downgrade by TD Cowen, reducing the price target to $16 from $
Neutral sentiment from hedge funds and insiders, with no significant trading trends.
In Q2 FY2026, revenue increased by 8.29% YoY to $24.29 million, net income grew by 47.53% YoY to $4.535 million, and EPS rose by 46.67% YoY to $0.22. Gross margin improved significantly by 25.15% YoY to 73.24%.
TD Cowen downgraded the price target from $19 to $16, maintaining a Hold rating. Despite this, the firm acknowledged strong Q2 results driven by development software and services.